Page last updated: 2024-08-23
paclitaxel and gw2974
paclitaxel has been researched along with gw2974 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Ajose-Adeogun, A; Coley, HM; Modjtahedi, H; Shotton, CF; Thomas, H | 1 |
Other Studies
2 other study(ies) available for paclitaxel and gw2974
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase 1; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Quinazolines; Receptor Protein-Tyrosine Kinases; Survivin | 2006 |